CD82 and colorectal carcinoma: Here, authors unveiled that LGALS3BP interacts with CD9/CD82 tetraspanins leading to ubiquitin-dependent degradation of β-catenin and suppression of Wnt signaling, thus explaining another mechanism through which LGALS3BP may exert its antitumor activity in CRC.